Thursday, March 23, 2023 | Back issues
Courthouse News Service Courthouse News Service

Hepatitis Drug

Dynavax Technologies stock fell from $11.60 to $4.10 this month after its hepatitis drug Heplisav-B was found to be dangerous, shareholders claim in two federal class actions.

SAN FRANCISCO – Dynavax Technologies stock fell from $11.60 to $4.10 this month after its hepatitis drug Heplisav-B was found to be dangerous, shareholders claim in two federal class actions.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading...